Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Incyte (INCY) -- Ignore unavailable to you. Want to Upgrade?

To: Cytokine1 who wrote (1436)	4/30/2000 12:23:00 AM
From: Vector1	Respond to of 3202

Thanks CYTO, Interesting interview. V1

To: Cytokine1 who wrote (1436)	4/30/2000 9:00:00 PM
From: John Solder	Respond to of 3202

Thanks for that article, it was excellent.

To: Cytokine1 who wrote (1436)	5/10/2000 2:32:00 AM
From: nigel bates	Respond to of 3202

But the market still doesn't get it... "Incyte shares fall on news of free access to genes" biz.yahoo.com "LOS ANGELES, May 9 (Reuters) - Shares of Incyte Pharmaceuticals Inc. (NasdaqNM:INCY - news), which supplies information about genes, fell as much as 11 percent on Tuesday after the company announced a contract to provide gene sequencing data free to the public. Shares of the Palo Alto, Calif.-based company were down 6-11/64 at 80, off earlier lows, in midafternoon trading on Nasdaq. Incyte announced a contract with the National Institutes of Health (NIH) to sequence DNA as part of the NIH's effort to create a public domain set of full-length expressed human and mouse genes, a resource seen as vital in unravelling how genes influence health and disease. All of the gene sequence data and clones from the project will be publicly available to the scientific research community. Currently, only about 6,000 full-length gene sequences from the more than 100,000 human genes are in the public domain. ``Some people may be concerned that the collaboration with the NIH might depreciate Incyte's database of genes, but I think it would be difficult for them to make a lot of money off of the database anyway,'' Albert Rauch, an analyst at First Union Securities, said. He suggested that Incyte is looking more toward the business of making genomic reagents for other companies and researchers rather than relying on revenue from access to the company's proprietary database. Reagents are used to evaluate gene function and identify new disease targets. ``They or someone else will have patents on the gene sequences. As more people have access to the sequences, there will be more demand for reagents,'' Rauch said. Incyte provides information about genes, related data management software, verified copies of genes and related reagents and services to pharmaceutical and biotechnology researchers.